LTRN
Price:
$3.02
Market Cap:
$32.57M
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an an...[Read more]
Industry
Biotechnology
IPO Date
2020-06-11
Stock Exchange
NASDAQ
Ticker
LTRN
According to Lantern Pharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.70. This represents a change of -43.79% compared to the average of -3.02 of the last 4 quarters.
The mean historical PE Ratio of Lantern Pharma Inc. over the last ten years is -21.22. The current -1.70 PE Ratio has changed 701.13% with respect to the historical average. Over the past ten years (40 quarters), LTRN's PE Ratio was at its highest in in the September 2024 quarter at -2.19. The PE Ratio was at its lowest in in the March 2019 quarter at -51.19.
Average
-21.22
Median
-13.67
Minimum
-53.84
Maximum
-2.91
Discovering the peaks and valleys of Lantern Pharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -2.91
Minimum Annual Increase = -65.08%
Minimum Annual PE Ratio = -53.84
Year | PE Ratio | Change |
---|---|---|
2023 | -2.91 | -37.51% |
2022 | -4.65 | -34.27% |
2021 | -7.08 | -65.08% |
2020 | -20.27 | -47.45% |
2019 | -38.57 | -28.36% |
The current PE Ratio of Lantern Pharma Inc. (LTRN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.88
5-year avg
-14.70
10-year avg
-21.22
Lantern Pharma Inc.’s PE Ratio is less than TFF Pharmaceuticals, Inc. (-0.02), less than Generation Bio Co. (-0.50), less than Lyra Therapeutics, Inc. (-0.12), greater than Immunome, Inc. (-2.16), less than Cue Biopharma, Inc. (-1.19),
Company | PE Ratio | Market cap |
---|---|---|
-0.02 | $288.80K | |
-0.50 | $73.47M | |
-0.12 | $11.45M | |
-2.16 | $684.71M | |
-1.19 | $65.88M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lantern Pharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lantern Pharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Lantern Pharma Inc.'s PE Ratio?
How is the PE Ratio calculated for Lantern Pharma Inc. (LTRN)?
What is the highest PE Ratio for Lantern Pharma Inc. (LTRN)?
What is the 3-year average PE Ratio for Lantern Pharma Inc. (LTRN)?
What is the 5-year average PE Ratio for Lantern Pharma Inc. (LTRN)?
How does the current PE Ratio for Lantern Pharma Inc. (LTRN) compare to its historical average?